Anavex Life Sciences Corp. today announced that it has filed the regulatory submission for its lead compound for the treatment of Alzheimer’s disease, ANAVEX 2-73, with the German Health Authority, BfArM, and the local Ethics Committee of Saxony.
The filing will enable the company to move forward with clinical studies for ANAVEX 2-73, and represents an integral achievement for Anavex.
“This regulatory filing marks an important milestone in the clinical development path for ANAVEX 2-73 and our strategy to aggressively complete a phase I and IIa study in healthy human volunteers and patients, respectively,” Dr. Cameron Durrant, executive chairman of Anavex stated in the press release.
The company will commence phase I dosing of healthy human volunteers with ANAVEX 2-73 in the near future; and a phase IIa study in patients with Alzheimer’s and Mild Cognitive Impairment may provide efficacy data and additional safety data, and is currently scheduled to commence in mid 2011.
“Our extensive pre-clinical program for ANAVEX 2-73 and the data generated so far offers the possibility of excellent safety and tolerability and encouraging signs of potential efficacy,” added Dr. Durrant.
Anavex is a biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of neurological diseases and cancer.
For more information visit www.anavex.com